The studies conducted by the<unk>  include the following: *<unk> -1<unk> -I; Finnish Multicentre Study of Prostatic Cancer) – ethinylestradiol 150 μg/day (1 mg/day initially) plus polyestradiol phosphate 80 mg/month (160 mg/month initially) versus orchiectomy for advanced prostate cancer *<unk> -2<unk> -II) – polyestradiol phosphate 160 mg/month (with or without low-dose aspirin) versus orchiectomy for advanced prostate cancer *<unk> -3<unk> -III) – cancelled *<unk> -4<unk> -IV) – polyestradiol phosphate 160 mg/month versus buserelin (with cyproterone acetate 300 mg/day initially to prevent gonadotropin flare) in advanced or metastatic prostate cancer *<unk> -5<unk> -V) – cancelled *<unk> -6<unk> -VI) – polyestradiol phosphate 240 month (320 mg/month initially) versus orchiectomy for advanced prostate cancer *<unk> -7<unk> -VII) – intermittent versus continuous androgen deprivation therapy for advanced prostate cancer * Other studies by the<unk>  Related trials A related study, by the Finnish Zoladex Multicentre Study<unk> , assessed polyestradiol phosphate versus goserelin for advanced prostate cancer. A British<unk>  also assessed polyestradiol phosphate 160 mg/month versus orchiectomy for advanced prostate cancer. The SPCG-5 trial assessed polyestradiol phosphate 240 mg/month versus combined androgen blockade (triptorelin or orchiectomy plus flutamide) for advanced prostate cancer.
FinnProstate Group
BC Cancer Agency
Hysterectomy Educational Resources and Services 
Prostate Cancer UK
JCO Clinical Cancer Informatics
International FOP Association
EP Europace
HPV Prevention and Control Board